Cara Therapeutics Reports Second Quarter 2021 Financial Results
– New Drug Application (NDA) Filing for KORSUVAâ„¢ Injection in CKD-aP under Priority Review by…
– New Drug Application (NDA) Filing for KORSUVAâ„¢ Injection in CKD-aP under Priority Review by…
Received approval for EMPAVELI™ (pegcetacoplan) – the first targeted C3 therapy – from U.S. Food and…
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical…
• Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. •…
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
– SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma…
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a…
Enhanced methods will provide proteoform-specific knowledge critical for understanding biological function and developing new biopharmaceutical…
Bagsværd, Denmark, 9 August 2021 — This company announcement discloses the data of the transaction(s)…
Potential to provide approximately $15 million a year in savings for life-enhancing medications SANTA MONICA,…
NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER)…
Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial…
Award reflects effort to maintain U.S. soy farmers’ global market share SAN FRANCISCO, Aug. 09,…
– Trial to Continue as Planned SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Â TRACON…
Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to…
Commercial and launch preparations on track to support potential U.S. FDA approval of FT218 for…
Study Shows TRUDHESAâ„¢ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes…
Top-line results from Phase IIb sepsis trial expected in Q2 2022 Phase IIb trial in…
PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company…